Skip to main content

bioAffinity Technologies, Inc 8-K, filed Nov 6, 2026

bioAffinity Technologies, Inc. (BIAF)

8-K 2026-11-06 For: 2026-11-06
View Original
Added on November 06, 2026

About this 8-K

bioAffinity Technologies, Inc filed this 8-K on November 6, 2026.

bioAffinity Technologies reported that CyPath Lung test unit sales increased 100% through Q3 2026, while third-quarter revenue fell to approximately $1.1 million and net loss widened to approximately $5.3 million from approximately $5.1 million. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 9.01: Financial statements and exhibits